Ładuje się......
Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells
BACKGROUND: Ingrowth of newly formed blood and lymph vessels (angiogenesis) from the limbus region into the cornea can be treated successfully by subconjunctival application of antiangiogenic agents. Currently, there are several angiogenesis inhibitors from various manufacturers available, such as v...
Zapisane w:
| Wydane w: | BMC Ophthalmol |
|---|---|
| Główni autorzy: | , , , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
BioMed Central
2018
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6288953/ https://ncbi.nlm.nih.gov/pubmed/30537942 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12886-018-0978-9 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|